![Heinz Schwer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Heinz Schwer
Amministratore Delegato presso Sloning Bio Technology GmbH
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Stefan Herr | M | - |
EMBL Ventures GmbH
![]() EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 23 anni |
Jan van den Brulle | M | - |
Sloning Bio Technology GmbH
![]() Sloning Bio Technology GmbH Miscellaneous Commercial ServicesCommercial Services Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability. It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications. In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers. | 19 anni |
Thomas Waldmann | M | - |
Sloning Bio Technology GmbH
![]() Sloning Bio Technology GmbH Miscellaneous Commercial ServicesCommercial Services Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability. It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications. In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers. | - |
Frank Mühlenbeck | M | 53 |
EMBL Ventures GmbH
![]() EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 9 anni |
George Rehm | M | 75 |
EMBL Ventures GmbH
![]() EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | - |
Rainer Wessel | M | 63 |
EMBL Ventures GmbH
![]() EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | - |
Garry Merry | M | - |
Sloning Bio Technology GmbH
![]() Sloning Bio Technology GmbH Miscellaneous Commercial ServicesCommercial Services Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability. It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications. In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers. | 15 anni |
Caroline Sauer | F | - |
EMBL Ventures GmbH
![]() EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 8 anni |
Lisa Egerer | M | - |
ViraTherapeutics GmbH
![]() ViraTherapeutics GmbH BiotechnologyHealth Technology ViraTherapeutics GmbH is a biopharmaceutical company that develops virus-based immunotherapeutics for cancer treatment. It specializes in the development of oncolytic cancer vaccines based on Vesicular Stomatitis Virus Glycoprotein G (VSV-GP). The company was founded by Dorothee Holm-von Laer in 2013 and is headquartered in Innsbruck, Austria. | - |
Cornelia Brosi | M | - |
EMBL Ventures GmbH
![]() EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 6 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Dorothee Holm-von Laer | F | - |
ViraTherapeutics GmbH
![]() ViraTherapeutics GmbH BiotechnologyHealth Technology ViraTherapeutics GmbH is a biopharmaceutical company that develops virus-based immunotherapeutics for cancer treatment. It specializes in the development of oncolytic cancer vaccines based on Vesicular Stomatitis Virus Glycoprotein G (VSV-GP). The company was founded by Dorothee Holm-von Laer in 2013 and is headquartered in Innsbruck, Austria. | 4 anni |
Octavian Schatz | M | - |
Sloning Bio Technology GmbH
![]() Sloning Bio Technology GmbH Miscellaneous Commercial ServicesCommercial Services Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability. It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications. In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers. | - |
Gudrun Horn | M | - |
Sloning Bio Technology GmbH
![]() Sloning Bio Technology GmbH Miscellaneous Commercial ServicesCommercial Services Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability. It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications. In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers. | - |
Thomas Matthes | M | 56 |
Sloning Bio Technology GmbH
![]() Sloning Bio Technology GmbH Miscellaneous Commercial ServicesCommercial Services Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability. It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications. In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers. | - |
Juliane Gassert | F | - |
EMBL Ventures GmbH
![]() EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively. | 6 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Germania | 13 | 86.67% |
Austria | 2 | 13.33% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Heinz Schwer
- Contatti personali